According to the report, the global testosterone replacement therapy market was valued at US$ 1,613.7 Mn in 2018 and is anticipated to expand at a CAGR of 4.4% from 2019 to 2027.
- According to Transparency Market Research’s latest report on the global testosterone replacement therapy market for the historical period 2017–2018 and forecast period 2019–2027, increasing incidence of testosterone deficiency, growing awareness among people regarding testosterone replacement therapy and significant pipeline of medications, are projected to drive the global testosterone replacement therapy market during the forecast period
- According to the report, the global testosterone replacement therapy market was valued at US$ 1,613.7 Mn in 2018 and is anticipated to expand at a CAGR of 4.4% from 2019 to 2027
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097
Rising incidence of testosterone deficiency: Key Drivers
- Testosterone deficiency, also known as hypogonadism, is characterized by diminished functioning of the male gonads that reduces testosterone secretion. This occurs mainly due to hypothalamic-pituitary axis dysfunction and/or testicular failure.
- Testosterone deficiency is one of the common health problems among men aged between 40 years and 79 years. The incidence of low testosterone levels in men aged over 60 years is estimated to be around 20% of the male population, and in population aged over 70 years, around 30%. The global prevalence of testosterone deficiency ranges from over 10% to 40% of the population.
- However, only around 9% patients with testosterone deficiency are being treated in the U.S. This is due to factors such as perceived risk of prostate cancer associated with current treatment therapy and lack of screening/tests for low testosterone. Therefore, increase in incidence rate of testosterone deficiency is expected to drive the testosterone replacement therapy products market in the near future.
Request for Analysis of COVID19 Impact on Testosterone Replacement Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1097
Rise in Geriatric Population with High Risk of Testosterone Deficiency Boost Market Growth
- The world population is aging rapidly, especially in some of the developed economies such as the U.S., most of Western Europe, and Japan. Developed economies present high rates of aging. This is attributed to improved health care infrastructure, policies, and advancement in health care facilities in these countries. Moreover, access to various diagnostic and treatment services has improved in the recent past especially in developed economies. This in turn has increased the life expectancy of the population.
- According to World Health Organization (WHO) estimates, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050 as compared to 524 million in 2010. The geriatric population would rise at the fastest rates in developed countries such as the U.K, Germany, the U.S., and Japan. However, Brazil, China, Thailand, and South Korea are also expected to have a large geriatric population base in shortest span of time in the near future.
- Testosterone levels decrease naturally as age increases beyond 30 years. However, in some cases significant decrease can lead to health problems. World population is rapidly aging. Therefore, with increasing population of age individuals the testosterone deficient men population would also grow, which in turn would increase the demand for testosterone replacement therapy in the global market. Hence, increase in the geriatric population is expected to fuel the growth of the testosterone replacement therapy market globally
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1097
Patent Expiry of Key Drugs and Entry of Generics Hamper Market
- The testosterone replacement therapy market is expected to experience a patent cliff during the forecast period. Expiration of key drug patents would affect the revenues of large pharmaceutical companies from TRT products. In addition, the generic versions of these drugs would further reduce the global market revenues as these would be priced much lower than their counterparts (branded drugs) that dominated the global market earlier.
- This factor is expected to have a profound effect on the overall testosterone replacement therapy products market, causing a drastic dip in market revenues. Moreover, approved ANDAs for most of these molecules will lead to intense generic competition.
- Therefore, patent expirations are likely to significantly impact and restrain the testosterone replacement therapy market in the near future.
Buy Testosterone Replacement Therapy Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1097<ype=S
Global Testosterone replacement therapy Market: Competitive Landscape
This report profiles major players in the global testosterone replacement therapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global testosterone replacement therapy market is highly consolidated, with top five players accounting for over 60% of the market.
Leading players operating in the global testosterone replacement therapy market are
- AbbVie, Inc.
- Allergan plc
- Bayer AG
- Endo Pharmaceuticals, Inc.
- Eli Lilly Company
- Kyowa Kirin International plc
- Mylan N.V.
- Novartis AG
- Pfizer, Inc.
- Clarus Therapeutics,
- Ferring Holding SA,
Global Testosterone replacement therapy Market: Key Developments
Key players in the global testosterone replacement therapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global testosterone replacement therapy market. A few product launches in the global testosterone replacement therapy market are:
- In April 2019, the U.S. FDA approved a generic version of testosterone gel 1.62% as replacement therapy for men with hypogonadism.
- In March 2019, the U.S. FDA approved Jatenzo, an oral testosterone capsule, manufactured by Clarus Therapeutics for the treatment of certain forms of hypogonadism.
Browse More Trending Reports by Transparency Market Research:
Rotary Evaporators Market: https://www.transparencymarketresearch.com/rotary-evaporators-market.html
Upper Extremities Disorders Treatment Market: https://www.transparencymarketresearch.com/upper-extremities-disorders-treatment-market.html
Mucormycosis Market: https://www.transparencymarketresearch.com/mucormycosis-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com